CN115628951A - Human hair lysate for trace drug detection and application thereof - Google Patents
Human hair lysate for trace drug detection and application thereof Download PDFInfo
- Publication number
- CN115628951A CN115628951A CN202211271459.6A CN202211271459A CN115628951A CN 115628951 A CN115628951 A CN 115628951A CN 202211271459 A CN202211271459 A CN 202211271459A CN 115628951 A CN115628951 A CN 115628951A
- Authority
- CN
- China
- Prior art keywords
- hair
- lysate
- human hair
- drug
- sample
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 48
- 229940079593 drug Drugs 0.000 title claims abstract description 46
- 238000001514 detection method Methods 0.000 title claims abstract description 34
- 239000006166 lysate Substances 0.000 title claims abstract description 24
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims abstract description 36
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims abstract description 26
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims abstract description 18
- 239000002202 Polyethylene glycol Substances 0.000 claims abstract description 14
- 229920001223 polyethylene glycol Polymers 0.000 claims abstract description 14
- PZBFGYYEXUXCOF-UHFFFAOYSA-N TCEP Chemical compound OC(=O)CCP(CCC(O)=O)CCC(O)=O PZBFGYYEXUXCOF-UHFFFAOYSA-N 0.000 claims abstract description 13
- 239000007853 buffer solution Substances 0.000 claims abstract description 9
- 239000011780 sodium chloride Substances 0.000 claims abstract description 9
- 108091005804 Peptidases Proteins 0.000 claims abstract description 8
- 239000004365 Protease Substances 0.000 claims abstract description 8
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims abstract description 8
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 claims abstract description 8
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 claims abstract description 8
- 239000000872 buffer Substances 0.000 claims description 11
- 230000002378 acidificating effect Effects 0.000 claims description 10
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 6
- 229920000604 Polyethylene Glycol 200 Polymers 0.000 claims description 2
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 claims description 2
- CBMPTFJVXNIWHP-UHFFFAOYSA-L disodium;hydrogen phosphate;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound [Na+].[Na+].OP([O-])([O-])=O.OC(=O)CC(O)(C(O)=O)CC(O)=O CBMPTFJVXNIWHP-UHFFFAOYSA-L 0.000 claims description 2
- 230000003779 hair growth Effects 0.000 claims description 2
- 239000008363 phosphate buffer Substances 0.000 claims 1
- 239000000243 solution Substances 0.000 abstract description 17
- 239000000523 sample Substances 0.000 description 28
- 102000011782 Keratins Human genes 0.000 description 14
- 108010076876 Keratins Proteins 0.000 description 14
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- 239000007788 liquid Substances 0.000 description 12
- 230000009089 cytolysis Effects 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 7
- 238000005336 cracking Methods 0.000 description 6
- 231100000640 hair analysis Toxicity 0.000 description 6
- 239000012472 biological sample Substances 0.000 description 5
- 239000003638 chemical reducing agent Substances 0.000 description 5
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- 230000001603 reducing effect Effects 0.000 description 4
- CWERGRDVMFNCDR-UHFFFAOYSA-N thioglycolic acid Chemical compound OC(=O)CS CWERGRDVMFNCDR-UHFFFAOYSA-N 0.000 description 4
- 108091005658 Basic proteases Proteins 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 238000000354 decomposition reaction Methods 0.000 description 3
- 230000003699 hair surface Effects 0.000 description 3
- 239000011259 mixed solution Substances 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 238000000197 pyrolysis Methods 0.000 description 3
- 230000002747 voluntary effect Effects 0.000 description 3
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- SJZRECIVHVDYJC-UHFFFAOYSA-N 4-hydroxybutyric acid Chemical compound OCCCC(O)=O SJZRECIVHVDYJC-UHFFFAOYSA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical group [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000004519 grease Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 239000011574 phosphorus Substances 0.000 description 2
- 229940113115 polyethylene glycol 200 Drugs 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 125000003396 thiol group Chemical group [H]S* 0.000 description 2
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 1
- BEQZHFIKTBVCAU-UHFFFAOYSA-N 2-amino-2-(2-chlorophenyl)-1-cyclohexanone Chemical compound C=1C=CC=C(Cl)C=1C1(N)CCCCC1=O BEQZHFIKTBVCAU-UHFFFAOYSA-N 0.000 description 1
- NGBBVGZWCFBOGO-UHFFFAOYSA-N 3,4-Methylenedioxyamphetamine Chemical compound CC(N)CC1=CC=C2OCOC2=C1 NGBBVGZWCFBOGO-UHFFFAOYSA-N 0.000 description 1
- SHXWCVYOXRDMCX-UHFFFAOYSA-N 3,4-methylenedioxymethamphetamine Chemical compound CNC(C)CC1=CC=C2OCOC2=C1 SHXWCVYOXRDMCX-UHFFFAOYSA-N 0.000 description 1
- PBVAJRFEEOIAGW-UHFFFAOYSA-N 3-[bis(2-carboxyethyl)phosphanyl]propanoic acid;hydrochloride Chemical compound Cl.OC(=O)CCP(CCC(O)=O)CCC(O)=O PBVAJRFEEOIAGW-UHFFFAOYSA-N 0.000 description 1
- CHZAMJVESILJGH-UHFFFAOYSA-N 3-[bis(2-cyanoethyl)phosphanyl]propanenitrile Chemical compound N#CCCP(CCC#N)CCC#N CHZAMJVESILJGH-UHFFFAOYSA-N 0.000 description 1
- JJGYGPZNTOPXGV-SSTWWWIQSA-N 6-Acetylmorphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)OC(C)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O JJGYGPZNTOPXGV-SSTWWWIQSA-N 0.000 description 1
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Divinylene sulfide Natural products C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 238000010306 acid treatment Methods 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229940025084 amphetamine Drugs 0.000 description 1
- GEHJBWKLJVFKPS-UHFFFAOYSA-N bromochloroacetic acid Chemical compound OC(=O)C(Cl)Br GEHJBWKLJVFKPS-UHFFFAOYSA-N 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- BJVWCKXHSNBHGB-UHFFFAOYSA-L disodium;chloride;hydroxide Chemical compound [OH-].[Na+].[Na+].[Cl-] BJVWCKXHSNBHGB-UHFFFAOYSA-L 0.000 description 1
- 238000003255 drug test Methods 0.000 description 1
- 239000003344 environmental pollutant Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 108010059345 keratinase Proteins 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 229960001252 methamphetamine Drugs 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- ZPIRTVJRHUMMOI-UHFFFAOYSA-N octoxybenzene Chemical compound CCCCCCCCOC1=CC=CC=C1 ZPIRTVJRHUMMOI-UHFFFAOYSA-N 0.000 description 1
- 229920002114 octoxynol-9 Polymers 0.000 description 1
- 229960003330 pentetic acid Drugs 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 231100000719 pollutant Toxicity 0.000 description 1
- 229940068918 polyethylene glycol 400 Drugs 0.000 description 1
- -1 polyoxyethylene octyl phenyl ether Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 238000004381 surface treatment Methods 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- TUQOTMZNTHZOKS-UHFFFAOYSA-N tributylphosphine Chemical compound CCCCP(CCCC)CCCC TUQOTMZNTHZOKS-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N1/00—Sampling; Preparing specimens for investigation
- G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
The invention discloses a human hair lysate for trace drug detection and application thereof, belonging to the technical field of drug detection and comprising the following components: 0.8-1.5mg/mL protease, 0.5-1.2% acetic acid, 2.6-7.8mg/mL sodium bisulfite, 2.9-4.1mg/mL sodium chloride, 12.5-20mg/mL tris (2-carboxyethyl) phosphine, 0.5-1.5% isopropanol, 0.5-1.5% polyethylene glycol and pH4-7 weak acid buffer solution, wherein the percentage is volume percentage.
Description
Technical Field
The invention relates to the technical field of drug detection, in particular to a human hair lysate for trace drug detection and application thereof.
Background
According to statistics, the number of people taking novel drugs in China increases by about 30% every year, wherein teenagers account for 86%. The abuse of novel drugs causes serious individual harm and social harm, and in order to effectively attack novel drug crimes and closely match the drug prohibition requirements of law enforcement departments such as public security, the analysts establish a series of accurate, rapid and high-sensitivity methods for qualitatively and quantitatively analyzing and detecting the novel drugs. The hair is used as a special carrier of the drug, has incomparable advantages of other test materials, is easy to obtain materials, convenient to carry and easy to store for a long time, and the drug is metabolized in the hair slowly and can exist for a long time, so that the analysis of the drug in the hair becomes a research hotspot of court science and clinical analysis and plays an increasingly important role. The drugs in the hair are mainly located in the cuticle and medulla layers of the hair and are bound with proteins, so that a hair sample needs to be pretreated before the drugs in the hair are detected, the drugs are released from the hair, and grease, sweat and various pollutants outside the hair are eliminated.
In the prior art, methods for hair treatment are divided into an acid treatment method and an alkali treatment method, for example, a rapid hair lysis solution disclosed in patent CN 110208072B, which consists of alkaline protease, thioglycolic acid, glycine, tris hydrochloride buffer, sodium chloride-sodium hydroxide buffer, polyethylene glycol octyl phenyl ether and dithiothreitol, wherein the alkaline protease is used for hydrolyzing protein peptide bonds under alkaline conditions, decomposing keratin and releasing drug small molecules; thioglycolic acid and dithiothreitol are used as reducing agents to promote the activity of keratinase; glycine, tris hydrochloride buffer solution, sodium chloride and sodium hydroxide buffer solution and the like provide a proper cracking environment; polyoxyethylene octyl phenyl ether is used to solubilize lipids to increase the permeability of cell membranes to antibodies. When a mercapto group-containing compound is used as a reducing agent, the mercapto group-containing reducing agent has a certain toxicity, and is accompanied by an odor, and the monothiol group-containing reducing agent generally needs to be in excess in order to ensure the destruction degree of disulfide bonds, and a dimercapto reducing compound such as Dithiothreitol (DTT) has a good reducing effect but has a disadvantage of being difficult to store in a solution, and in order to ensure the effect, DTT is preferably prepared as it is. Under acidic conditions, the commonly used cleaved and reduced product is a phosphorus-containing compound, such as Tris (2-carboxyethyl) phosphine (TECP), which is slightly soluble in water, easy to store and can be operated without a protective gas), has a stronger reducing power for disulfide bonds than DTT, and has a wide pH tolerance range. Patent CN 101979428B discloses a preparation method and use of an animal hair dissolving agent and a keratin solution, which uses tris (2-carboxyethyl) phosphine hydrochloride, tris (2-cyanoethyl) phosphine or tri-n-butylphosphine as main components for separating keratin.
Under the acidic or neutral condition, the medicine release is incomplete, while the content of the poison and the metabolite thereof in the hair is very low, only in ng/mg level, and the detection accuracy is affected by the incomplete medicine release.
Disclosure of Invention
In view of the technical defects, the invention aims to provide a human hair lysate for trace drug detection, which is characterized by comprising the following components: 0.8-1.5mg/mL protease, 0.5-1.2% acetic acid, 2.6-7.8mg/mL sodium bisulfite, 2.9-4.1mg/mL sodium chloride, 12.5-20mg/mL tris (2-carboxyethyl) phosphine, 0.5-1.5% isopropanol, 0.5-1.5% polyethylene glycol and pH4-7 weakly acidic buffer, wherein the% is volume percent.
Preferably, the following components are included: 0.9-1.1mg/mL protease, 0.7-1.0% acetic acid, 3.6-4.2mg/mL sodium bisulfite, 3.5-4.1mg/mL sodium chloride, 16.6-18.7mg/mL tris (2-carboxyethyl) phosphine, 1.1-1.5% isopropanol, 1.1-1.5% polyethylene glycol and pH4-7 weak acidic buffer, wherein the% is volume percent. Preferably, the weakly acidic buffer solution with the pH value of 4-7 is at least one of 0.01-1mol/L phosphate buffer solution, citric acid buffer solution, acetic acid buffer solution and disodium hydrogen phosphate-citric acid buffer solution, the buffer solution is used for catalyzing and decomposing keratin, a proper environment is provided for hair surface treatment, hair surface grease decomposition is facilitated under an acidic condition, and the phenomenon that a drug entering a lysate is combined with protein again is effectively avoided under the acidic condition.
Preferably, the polyethylene glycol is PEG-200 or PEG-400 or a mixture of the two.
In view of the technical shortcomings, the invention also aims to provide an application of human hair lysate for trace drug detection, which is characterized in that: the lysate is used for cracking hair and releasing drug components in the hair.
Preferably, the hair is a hair within 3cm in length from the hair growth end.
Preferably, the hair is hair taken from the human body.
Preferably, the amount of lysate is 150 ± 10 μ L per mg of hair.
Preferably, the lysis mixture obtained by lysing the hair with the lysis solution is adjusted to a pH of 8 to 9 before the test is performed.
The invention has the beneficial effects that: 1.2, the invention takes tri (2-carboxyethyl) phosphine as a reducing agent, is easy to store, and the disulfide bonds between the tri (2-carboxyethyl) phosphine keratins are broken to promote the decomposition of the keratin; 3. isopropanol and polyethylene glycol are dissolved in water, and are added, so that the components of the composition are in a uniform state, the overall polarity of the solution is changed, the interaction force between tris (2-carboxyethyl) phosphine and keratin is increased, and the disulfide bond in the keratin is favorably broken; 4. except gamma-hydroxybutyric acid, the common drugs such as 6 acetylmorphine, morphine, methamphetamine, amphetamine, 3,4 methylenedioxyamphetamine, 3,4 methylenedioxymethamphetamine, ketamine, norketamine, gamma-hydroxybutyric acid and the like are low in water solubility or insoluble in water, isopropanol and polyethylene glycol are added to change the medium environment, reduce the interaction force between drug molecules and keratin, promote the drug molecules to be released into a lysate, promote the drug to be released from the keratin, and improve the release amount of the drug, so that the subsequent detection accuracy is improved; 5. acetic acid is added to soften the hair scales on the hair surface, so that the subsequent solvent can permeate the hair scales, and the permeation speed of isopropanol and polyethylene glycol is accelerated.
Detailed Description
The technical solutions in the embodiments of the present invention will be clearly and completely described below with reference to the embodiments of the present invention, and it is obvious that the described embodiments are only a part of the embodiments of the present invention, and not all of the embodiments. All other embodiments, which can be obtained by a person skilled in the art without making any creative effort based on the embodiments in the present invention, belong to the protection scope of the present invention.
Example 1:
sample acquisition: collecting hair from the root of the hair of a person to be tested, obtaining a hair sample, and keeping the hair within 3cm from the hair growing end by taking the hair growing end as a reference.
Sample a: the person to be tested is a voluntary drug-dropping person, the sample is obtained 101mg, the sample hair is cut into thin sections by scissors, four parts are equally divided and respectively marked as D-A, T-A1, T-A2 and T-A3, and each part is about 5mg;
sample B: the person to be tested is a voluntary drug-dropping person, 133mg of sample is obtained, the sample hair is cut into thin sections by scissors, four parts are equally divided and are respectively marked as D-B, T-B1, T-B2 and T-B3, and each part is about 5mg;
sample C: the person to be tested is a voluntary drug-dropping person, samples are obtained 97mg, sample hair is cut into thin sections by scissors, four parts are equally divided and respectively marked as D-C, T-C1, T-C2 and T-C3, and each part is about 5mg;
wherein, the samples D-A, D-B and D-C adopt a commercial cracking agent which takes DTT as a main reduction component of a disulfide bond to respectively detect the samples D-A, D-B and D-C, taking the operation steps of the samples D-A as an example, the steps are as follows:
step one, adding commercially available DTT (diethylenetriamine pentaacetic acid) serving as a main reducing component of a disulfide bond and alkaline protease serving as a cracking agent of a hydrolysis component into a 1.5mL centrifugal tube, wherein the volume of the cracking agent is about 750 mu L;
step two, transferring the pre-obtained and cut hair sample D-A into a centrifuge tube;
step three, carrying out ultrasonic water bath, setting the temperature to be 25 ℃, and setting the time to be 6 minutes;
and step four, taking out the sample, standing for 1 minute, sucking the upper liquid, adding the upper liquid into a sample adding area of a sensing chip of the detector, adding 4 drops of sample adding amount, about 80 mu L of sample adding amount, waiting for about 6-10 minutes, inserting the sample adding area into a full biological sample Drug analyzer for detection, and recording a detection result, wherein the model of the full biological sample Drug analyzer is Drug Test 5900H.
The operations of the samples D-B and D-C are the same as the steps, and the detection results are recorded respectively after the detection is finished.
Example 2:
the hair lysate is prepared according to the proportion, in the embodiment, the proportion of each component is as follows: 1.1mg/mL protease, 1.0% acetic acid, 4.2mg/mL sodium bisulfite, 4.1mg/mL sodium chloride, 18.7mg/mL tris (2-carboxyethyl) phosphine, 1.5% isopropanol, 1.5% polyethylene glycol 200, acetic acid buffer ph =6, where% is volume percent.
Samples T-A1, T-B1 and T-C1 were each detected using the cleavage agent of this example, and the sample T-A 1 The operation steps are as follows:
step one, adding the lysis solution in the embodiment into a 1.5mL centrifuge tube, wherein the lysis solution is about 750 mu L;
step two, transferring the pre-obtained and cut hair sample T-A1 into a centrifuge tube;
step three, carrying out ultrasonic water bath, setting the temperature to be 30-35 ℃ and the time to be 10 minutes;
step four, adjusting the pH value of the hair drug release mixed solution to 8-9 by using a sodium hydroxide solution;
and step five, taking out the sample, standing for 1 minute, sucking the upper liquid, adding the upper liquid into a sample adding area of a sensing chip of the detector, adding 4 drops of sample adding amount, about 80 mu L, waiting for about 6-10 minutes, inserting the whole biological sample drug analyzer for detection, and recording the detection result.
The operation of the samples T-B1 and T-C1 is the same as the steps, and the detection results are recorded respectively after the detection is finished. Example 3:
the hair lysate is prepared in proportion, in the embodiment, the proportion of each component is as follows: 1.0mg/mL protease, 0.7% acetic acid, 3.9mg/mL sodium bisulfite, 4.1mg/mL sodium chloride, 17.5mg/mL tris (2-carboxyethyl) phosphine, 1.3% isopropanol, 1.3% 1 mixture of polyethylene glycol 200 and polyethylene glycol 400, pH4-7 weak acidic buffer, wherein% is volume percent.
Samples T-A2, T-B2 and T-C2 were each assayed using the cleavage agent of this example, and sample T-A was used 1 The operation steps are as follows:
step one, adding the lysis solution in the embodiment into a 1.5mL centrifuge tube, wherein the lysis solution is about 750 mu L;
step two, transferring the pre-obtained and cut hair sample T-A2 into a centrifuge tube;
step three, carrying out ultrasonic water bath, setting the temperature to be 35 ℃, and setting the time to be 15 minutes;
step four, adjusting the pH value of the hair drug release mixed solution to 8-9 by using a sodium hydroxide solution;
and step five, taking out the sample, standing for 1 minute, sucking the upper layer liquid, adding the upper layer liquid into a sample adding area of a sensing chip of the detector, adding 4 drops of sample adding amount, about 80 mu L of sample adding amount, waiting for about 6-10 minutes, inserting the whole biological sample drug analyzer for detection, and recording the detection result.
The operation of the samples T-B2 and T-C2 is the same as the steps, and the detection results are recorded respectively after the detection is finished. Example 4:
the hair lysate is prepared according to the proportion, in the embodiment, the proportion of each component is as follows: 1.1mg/mL protease, 4.2mg/mL sodium bisulfite, 4.1mg/mL sodium chloride, 18.7mg/mL tris (2-carboxyethyl) phosphine, 3mg/mL urea, pH =6 acetate buffer, wherein% is volume percent.
The samples T-A3, T-B3 and T-C3 are respectively detected by adopting the cracking agent in the embodiment, taking the operation steps of the sample T-A3 as an example, the steps are as follows:
step one, adding the lysis solution in the embodiment into a 1.5mL centrifuge tube, wherein the lysis solution is about 750 mu L;
step two, transferring the pre-obtained and cut hair sample T-A3 into a centrifuge tube;
step three, performing ultrasonic water bath, setting the temperature to be 30-35 ℃, and setting the time to be 10 minutes;
step four, adjusting the pH value of the hair drug release mixed solution to 8-9 by using a sodium hydroxide solution;
and step five, taking out the sample, standing for 1 minute, sucking the upper liquid, adding the upper liquid into a sample adding area of a sensing chip of the detector, adding 4 drops of sample adding amount, about 80 mu L, waiting for about 6-10 minutes, inserting the whole biological sample drug analyzer for detection, and recording the detection result.
The operation of the samples T-B3 and T-C3 is the same as the steps, and the detection results are recorded respectively after the detection is finished.
The detection results are as follows:
table 1: sample detection condition
Compared with the existing phosphorus-containing decomposition liquid, the pyrolysis liquid simplifies the processing steps, shortens the processing time, greatly improves the processing efficiency of the pyrolysis liquid, is easy to store, prolongs the storage life of the pyrolysis liquid, adopts water-soluble reagents as medium reagents, is easy to carry out subsequent processing, dissolves isopropanol and polyethylene glycol in water, adds isopropanol and polyethylene glycol, enables the components of the composition to be in a uniform state, changes the overall polarity of the solution medium, increases the interaction force between tris (2-carboxyethyl) phosphine and keratin, and is beneficial to the breakage of disulfide bonds in the keratin; the acetic acid is a solvent commonly used in chemical reaction, and is matched with the isopropanol and the polyethylene glycol to change the medium environment, reduce the interaction force between drug molecules and keratin, promote the drug molecules to be released into a lysate, promote the drug to be released from the keratin, improve the release amount of a drug, enable the drug to be easily detected, and increase the subsequent detection accuracy.
It will be apparent to those skilled in the art that various changes and modifications may be made in the present invention without departing from the spirit and scope of the invention. Thus, if such modifications and variations of the present invention fall within the scope of the claims of the present invention and their equivalents, the present invention is also intended to include such modifications and variations.
Claims (8)
1. A human hair lysate for trace drug detection is characterized by comprising the following components: 0.8-1.5mg/mL protease, 0.5-1.2% acetic acid, 2.6-7.8mg/mL sodium bisulfite, 2.9-4.1mg/mL sodium chloride, 12.5-20mg/mL tris (2-carboxyethyl) phosphine, 0.5-1.5% isopropanol, 0.5-1.5% polyethylene glycol and pH4-7 weakly acidic buffer, wherein the% is volume percent.
2. The human hair lysate for trace drug detection according to claim 1, comprising the following components: 0.9-1.1mg/mL protease, 0.7-1.0% acetic acid, 3.6-4.2mg/mL sodium bisulfite, 3.5-4.1mg/mL sodium chloride, 16.6-18.7mg/mL tris (2-carboxyethyl) phosphine, 1.1-1.5% isopropanol, 1.1-1.5% polyethylene glycol and pH4-7 weakly acidic buffer, wherein the% is volume percent.
3. The human hair lysate for trace drug detection according to claim 1 or 2, wherein the pH4-7 weak acid buffer is at least one of a phosphate buffer, a citric acid buffer, an acetic acid buffer, and a disodium hydrogen phosphate-citric acid buffer of 0.01-1 mol/L.
4. A human hair lysate used in the detection of trace drugs according to claim 1 or 2, characterised in that the polyethylene glycol is PEG-200 or PEG-400 or a mixture of both.
5. The use of a human hair lysate for trace drug detection according to claim 1 or 2, wherein the lysate is used to lyse hair, resulting in the release of drug components from hair.
6. Use of a human hair lysate according to claim 5, wherein the hair is a hair having a length of less than 3cm from the hair growth end.
7. Use of a human hair lysate according to claim 5, wherein the hair is human hair.
8. Use of a human hair lysate according to claim 5, in which the lysate is used in an amount of 150 ± 10 μ L per mg of hair.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211271459.6A CN115628951A (en) | 2022-10-18 | 2022-10-18 | Human hair lysate for trace drug detection and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211271459.6A CN115628951A (en) | 2022-10-18 | 2022-10-18 | Human hair lysate for trace drug detection and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN115628951A true CN115628951A (en) | 2023-01-20 |
Family
ID=84906493
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202211271459.6A Pending CN115628951A (en) | 2022-10-18 | 2022-10-18 | Human hair lysate for trace drug detection and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN115628951A (en) |
Citations (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5690956A (en) * | 1995-09-27 | 1997-11-25 | Sdg, Inc. | Hair care perming agent |
| WO2000077235A1 (en) * | 1999-06-16 | 2000-12-21 | University Of Cincinnati | Agent and process for isolation of extra-chromosomal nucleic acids |
| US20050037386A1 (en) * | 2003-05-05 | 2005-02-17 | Drug Risk Solutions, L.L.C. | Composition and processes for analysis of pharmacologic agents in biological samples |
| US20090269791A1 (en) * | 2008-04-29 | 2009-10-29 | Psychemedics Corporation | Non-proteolytic method for the determination of analytes in keratinized structures |
| US20100029925A1 (en) * | 2008-05-23 | 2010-02-04 | Life Technologies Corporation, A Delaware Corporation | Methods and kits for extraction of dna |
| US20110159485A1 (en) * | 2009-09-16 | 2011-06-30 | Life Technologies Corporation | Lysis Buffers for Extracting Nucleic Acids |
| US20150064719A1 (en) * | 2013-08-28 | 2015-03-05 | Psychemedics Corporation | Integrity testing of hair samples |
| US20160024559A1 (en) * | 2014-07-24 | 2016-01-28 | The Bode Technology Group, Inc. | Specimen collection with reagent lined collectors |
| US20170067803A1 (en) * | 2015-09-09 | 2017-03-09 | Drawbridge Health, Inc. | Systems, Methods, and Devices for Sample Collection, Stabilization and Preservation |
| US20170074869A1 (en) * | 2014-02-07 | 2017-03-16 | European Molecular Biology Laboratory | Proteomic sample preparation using paramagnetic beads |
| US20170138940A1 (en) * | 2014-04-28 | 2017-05-18 | Magnamedics Gmbh | Method for isolating trace components from a biological liquid sample |
-
2022
- 2022-10-18 CN CN202211271459.6A patent/CN115628951A/en active Pending
Patent Citations (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5690956A (en) * | 1995-09-27 | 1997-11-25 | Sdg, Inc. | Hair care perming agent |
| WO2000077235A1 (en) * | 1999-06-16 | 2000-12-21 | University Of Cincinnati | Agent and process for isolation of extra-chromosomal nucleic acids |
| US20050037386A1 (en) * | 2003-05-05 | 2005-02-17 | Drug Risk Solutions, L.L.C. | Composition and processes for analysis of pharmacologic agents in biological samples |
| US20090269791A1 (en) * | 2008-04-29 | 2009-10-29 | Psychemedics Corporation | Non-proteolytic method for the determination of analytes in keratinized structures |
| US20100029925A1 (en) * | 2008-05-23 | 2010-02-04 | Life Technologies Corporation, A Delaware Corporation | Methods and kits for extraction of dna |
| US20110159485A1 (en) * | 2009-09-16 | 2011-06-30 | Life Technologies Corporation | Lysis Buffers for Extracting Nucleic Acids |
| US20150064719A1 (en) * | 2013-08-28 | 2015-03-05 | Psychemedics Corporation | Integrity testing of hair samples |
| US20170074869A1 (en) * | 2014-02-07 | 2017-03-16 | European Molecular Biology Laboratory | Proteomic sample preparation using paramagnetic beads |
| US20170138940A1 (en) * | 2014-04-28 | 2017-05-18 | Magnamedics Gmbh | Method for isolating trace components from a biological liquid sample |
| US20160024559A1 (en) * | 2014-07-24 | 2016-01-28 | The Bode Technology Group, Inc. | Specimen collection with reagent lined collectors |
| US20170067803A1 (en) * | 2015-09-09 | 2017-03-09 | Drawbridge Health, Inc. | Systems, Methods, and Devices for Sample Collection, Stabilization and Preservation |
Non-Patent Citations (1)
| Title |
|---|
| 王江波等: "基于新型还原剂羊毛角蛋白的高效溶解", 《材料导报 Ｂ：研究篇》, 31 December 2012 (2012-12-31), pages 7 - 10 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Valente et al. | Hair as the sample in assessing morphine and cocaine addiction. | |
| CN108844922B (en) | Method for rapidly detecting drugs in hair | |
| CN101115388B (en) | Cell permeabilization and stabilization reagent and method of use | |
| Humphrey et al. | Observations on the presence of plasma proteins in skin and tendon | |
| WO1987000413A1 (en) | Non-invasive collection means and method | |
| EP0038935B1 (en) | Process for the immunological determination of enzymes, agent for its realization and its use | |
| Nimmo Wilkie et al. | Morphometric analyses of the skin of dogs with atopic dermatitis and correlations with cutaneous and plasma histamine and total serum IgE | |
| CN111638106A (en) | Dry chemical analysis quality control substance for urine | |
| CN103454410A (en) | Biologically-safe quality control material for blood tester and preparation method thereof | |
| CN106706929A (en) | Method for detecting human body fatigue by utilizing saliva | |
| US5437985A (en) | Conservative whole blood sample preparation technique | |
| Tripathi et al. | Biochemical reference intervals for koi (Cyprinus carpio) | |
| EP0867720B1 (en) | Method of detecting hematopoietic progenitor cells | |
| CN115628951A (en) | Human hair lysate for trace drug detection and application thereof | |
| Frimpter et al. | Conjugated amino acids in plasma of patients with uremia | |
| Ugel | Bovine keratohyalin: anatomical, histochemical, ultrastructural, immunologic, and biochemical studies | |
| CN106885803B (en) | A kind of strong antijamming capability and the high enzyme process ethyl alcohol detection reagent of accuracy | |
| Groff et al. | A new and rapid determination of pyridinium aldoximes in blood and urine | |
| EP1106683A3 (en) | A method for providing long term stability to cells for diagnostic testing | |
| Pedersen et al. | Blood chemistry and hematology of elk | |
| Vu Duc | EMIT tests for drugs of abuse: interference by liquid soap preparations. | |
| Jefferys et al. | Fungistasis in soils | |
| CN103694309A (en) | Method for extracting and detecting fish sperm membrane protein | |
| JP2001527530A (en) | Anticoagulation of blood, plasma or synovial fluid products | |
| CN115060562B (en) | Hair drug trace detection extracting solution and preparation and use methods thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |